IP Library Granted Patent US 7,410,946
Granted Patent B2
US 7,410,946 · App. 10/332,705 · Granted Aug 12, 2008

Method for treating damage in intact skin comprising administering a composition comprising basic milk growth factors in amounts higher than those in milk

Assignee: Novozymes Biopharma Au Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,410,946
App. No.
10/332,705
Granted
Aug 12, 2008
Kind
B2
Abstract

This invention relates to a method for treating skin damage, comprising the step of administration of a pharmaceutical or dermatological composition of basic milk factors to the area of the skin of a subject in need of such treatment. The invention further relates to a method for cosmetically treating the aged appearance of skin. The skin damage may be the result of normal biological ageing, environmental factors, dermatological disorders, medical treatments, surgical treatments and/or medical conditions. The aged appearance of skin may be attributed to wrinkles, blemishes, sagging, hyperpigmentation, changes to skin thickness and/or a rough appearance. In a preferred embodiment, the subject in need of such treatment requires the enhancement of the youthful appearance of their skin. The invention further relates to compositions for the treated of these conditions.

Claims (7)

1. A method for treating skin damage, the method comprising: topically administering to an area of substantially intact skin of a mammal in need thereof an effective amount of a composition for increasing dermal cellularity and/or stimulating collagen production, and/or inhibiting matrix-metalloproteinase 1 production in the skin, the composition comprising a plurality of basic milk factors having basic to approximately neutral isoelectric points, the milk factors being present at concentrations greater than that found in the lactational secretion from which they were derived and separated from the lactational secretion from which they were derived, the plurality of basic milk factors comprising at least one basic milk factor that is insulin-like growth factor 1 (IGF-1) or transforming growth factor β2 (TGF-β2), the basic milk factors having a molecular weight of at least approximately 5,000 Da, wherein upon administration of the composition the at least one basic milk factor having a molecular weight of at least approximately 5000 Da passes through the uppermost layers of skin having barrier function to exert a biological effect on an underlying competent cell.

2. The method according to claim 1 wherein the total concentration of basic milk factors is greater than or equal to about 0.25 mg/mL of composition.

3. The method according to claim 1 wherein the total concentration of basic milk factors is greater than or equal to about 0.5 mg/mL of composition.

4. The method according to claim 1 , wherein the composition is obtained by a method comprising adsorbing the milk factors to a cation exchange matrix, eluting the milk factors from the matrix, acidifying and concentrating the eluate.

5. The method according to claim 1 , wherein the method stimulates production of collagen in the substantially intact skin.

6. The method according to claim 1 , wherein the method increases dermal cellularity in the substantially intact skin.

7. The method according to claim 1 , wherein the method inhibits production of matrix metalloproteinase 1 in the substantially intact skin.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2010
From: NOVOZYMES BIOPHARMA AU LIMITED
To: NOVOZYMES BIOPHARMA DK A/S
Reel/Frame 025436/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2010
From: NOVOZYMES BIOPHARMA AU LIMITED
To: NOVOZYMES BIOPHARMA DK A/S
Reel/Frame 025350/0127 →
CHANGE OF NAME Recorded Jun 6, 2008
From: NOVOZYMES GROPEP LIMITED
To: NOVOZYMES BIOPHARMA AU LIMITED
Reel/Frame 021050/0930 →
CHANGE OF NAME Recorded Jun 5, 2008
From: GROPEP LIMITED
To: NOVOZYMES GROPEP LIMITED
Reel/Frame 021118/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2003
From: RAYNER, TIMOTHY EDWARD; COWIN, ALLISON JUNE; BELFORD, DAVID ANDREW
To: GROPEP LIMITED
Reel/Frame 013827/0939 →
Priority Claims (1)
AU PQ8786 · Jul 13, 2000 · national
Continuity (1)
Related Publication 20040081673A1 · Apr 29, 2004